Allos Therapeutics files $150 million shelf registration

By Laura Lutz

Des Moines, May 23 - Allos Therapeutics, Inc. filed a $150 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers common stock, preferred stock, depositary shares, debt securities, warrants and units. Securities may be structured as convertibles.

The filing includes $46 million of previously registered but unsold securities.

Proceeds will be used for clinical and preclinical research and development, for the manufacture of preclinical and clinical drug supply and for general corporate purposes.

Allos is a biopharmaceutical company based in Westminster, Colo.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.